

Applicants: Peter S. Linsley et al.

U.S. Serial No.: 09/454,651

Filed: December 6, 1999

Page 18

-- CTLA4Ig MUTANT FUSION PROTEIN

AYPPPY (SEQ ID NO: 25)	+++	+++	+++	-
MAPPPY (SEQ ID NO: 26)	++	+	++	-
MYAPPY(SEQ ID NO: 27)	+	-	+	-
MYPAPY(SEQ ID NO: 28)	+++	+++++	+++	-
MYPPAY(SEQ ID NO: 29)	+++	-	+	-
MYPPPA(SEQ ID NO: 30)	+++	++	+++	-
AAPPPY(SEQ ID NO: 31)	+	++	+++	-

D23

CD28Ig MUTANT FUSION PROTEIN

MYPPAY(SEQ ID NO: 32)	-	-	-	-
MYPPPA(SEQ ID NO: 33)	-	-	-	+ --.

In the Claims:

✓ ✓ ✓ ✓ ✓
Please delete claims 11-19, 39, and 41-42 without prejudice to pursue the subject matter of these claims in another application to be filed in the future.

Please amend claims 38 and 40 as follows:

--38. (Amended) A method for inhibiting functional CTLA4 positive T cell interactions with B7 positive cells comprising contacting the CTLA positive cells with a ligand for CTLA4, in an amount effective to interfere with reaction of endogenous B7 antigen with the CTLA4 positive cells, wherein the ligand for CTLA4 is a soluble B7 comprising the extracellular domain of B7 having the sequence disclosed in SEQ ID NO:23. --

D24